Recently, AmacaThera has raised $3.25 million in seed round financing. This round of financing was led by Sprout BioVentures and Viva Biotech, and investors included Gray Sky Venture Partners.

AmacaThera will use this round of financing for the first phase of opioid substitution, validating the theory through Phase I clinical trials and promoting AmacaThera's development of drug delivery platform technology.

AmacaThera is a Toronto-based biotechnology company dedicated to the development and application of a unique injectable hydrogel platform technology. AmacaThera's research team includes Dr. Molly Shoichet and Dr. MIKE COOKE. The main project is to develop a combination product for controlling postoperative pain. AmacaThera envisions the use of its patented technology to continuously and controllably release multiple therapeutic agents to biocompatible hydrogels. Their first product was AMT-143, which aims to replace opioids and control pain after surgery.

Mike Serrano-Wu, a partner at Sprout BioVentures, said: "We have partnered with Molly and Mike to break through the technical bottlenecks in hydrogel packaging therapy. The unique inverse thermal gel properties of AMT-143 will give AmacaThera more opportunities to improve significantly. Postoperative care of the patient."

Todd McIntyre, a partner at Gray Sky Venture Partners, said: "Gray Sky is pleased to work with the AmacaThera team to bring AMT-143 to market. There is a large unmet need for non-opioid pain control after surgery, and AmacaThera's technology will Provides a unique solution for sustained release of pain control drugs."

RT-PCR Test Reagent Kit

The RT-PCR Test Reagent Kit is a real-time, RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in oropharyngeal and nasopharyngeal swab specimens from individuals suspected of COVID-19 by their healthcare provider. This test is also for use with anterior nasal swab specimens that are collected using the COVID-19 Test Collection Kit when used consistent with its authorization.
Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in the upper respiratory specimens during the acute phase of infection.
Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status.
Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.
Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations,patient history,and epidemiological information.

PCR test Kit,PCR testing Kit,PCR detection kit,RT-PCR test reagent kit,RT-PCR test reagent

Shenzhen Uni-medica Technology Co.,Ltd , https://www.nbunimed-global.com